Thanks to the latest research, we can now target specific migraine pathways.
Aducanumab, the first Alzheimer’s-modifying therapy, submitted to the FDA. Can Biogen recover from their errors?
The field of MS research has had amazing success in the last two decades.
One day, one of the trials in Alzheimer’s disease will be positive. We think this trial may already be underway.